AzTrials
AzTrials

Effects of Smoking on InfantNCT00563966

The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy

An observational study of Effects of Smoking on Infant, run by Hadassah Medical Organization at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

It is generally understood that smoking during pregnancy has deleterious effects on the developing fetus, although research on smoking during pregnancy has been limited in focus, with most studies focused on birth weight of newborns and children's behavioral disturbances. Read more about this study

Who is it for?
Ages 22 to 35 years, women onlyHealthy volunteers can take part
Conditions the study is for
Effects of Smoking on Infant
How many people
200 participants
Where
1 siteIsrael
Study dates
Apr 2008to Dec 2008
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Women who smoked during pregnancy

Who may be able to join

  • Smokes at least 10 cigarettes a day
  • No abuse of alcohol or drugs
  • No chronic physical disability
  • 22-35 years of age
  • Living with partner
  • Speaks English, Hebrew, or Russian
  • Natural conception

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

David Mankuta, MD contact

97226776484

mankutad@gmail.com

Israel1 site, 1 recruiting
  • Hadassah Medical Organization

    Jerusalem

    David Mankuta, MD

    Rachel Bachner, PhD

    Recruiting

Other trials in Israel

About this study

Official title: The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy: Genes, Hormones and Psychological Modulators

It is generally understood that smoking during pregnancy has deleterious effects on the developing fetus, although research on smoking during pregnancy has been limited in focus, with most studies focused on birth weight of newborns and children's behavioral disturbances. However, little is known about the neurobiological underpinnings of nicotine-related developmental deficits and even less is known about genetic and environmental factors that may exacerbate the risk for such deficits in some children. In this study, we propose to examine the relation between antenatal exposure to nicotine and infants' stress-responses before and after birth (2-days, 6-months) and its moderation of by family-based stressors and genes related to nicotine metabolism and stress responsivity.

We hypothesize that the risk imposed on infants by antenatal exposure to nicotine is moderated by genotype that influences functioning of the HPA axis, metabolism of nicotine, and stress-levels and parenting that influence the development of neural substrates (HPA axis) and infants' capacity to cope with stress. There is a growing consensus that Gene x Environmental (G x E) interplay likely mediated by epigenetic effects constitute one of the central mechanism by which complex disorders develop. Our proposal offers an exceptional paradigm to explore the association between genes, environment, and G x E interactions on the neural and behavior response of children to stressful challenges.

Read the detailed description

Detailed Description of the Proposed Research

Design overview. A large cohort of pregnant women will be recruited, and those who meet criteria will be divided into two groups according to their testimony regarding their smoking behavior and saliva cotinine screening, as in our previous studies. At 3-time points, the antenatal period, 2-days and 6-months of age; we will assess infants' responses to challenges using biochemical, behavioral, and subjective measures. The challenges selected are "proven" stressors and previous research has demonstrated their effectiveness in eliciting stress-reactions (e.g., increased cortisol). In parallel, we will obtain an obstetric history (from medical records), demographics, measure of symptomology, information on smoking and drinking habits, life stresses, and family cohesion at each time point, plus information about mothers' feelings/behavior and mothers' ratings of infants "regulatory" behavior after birth. The antenatal and neonatal sessions will be carried out in Hadassah Hospital and the 6-month session in the developmental laboratory at Hebrew University. Genetic material will be collected from parents and their infant at childbirth.

Recruitment Women smokers will be recruited will be recruited by nurses in well-baby clinics (where physicians do routine prenatal check-ups), gynecologists, midwives, and by advertisement. In addition, we will recruit women at the time of routine checks in Hadassah hospital (Nuchal translucency test) at 12 weeks, triple/quadra test blood testing at 16 weeks, early (14-16 weeks) and advanced (20-22 week) fetal anatomy scan, and glucose test at 24-28 weeks) (supervised by Dr. Mankuta). In all, we will recruit 150 women for the "smoking" group, using the following inclusion criteria: smokes at least 10 cigarettes a day (i.e., habitual smokers) no abuse of alcohol or drugs, no chronic physical disability, 22-35 years of age, living with partner, speaks English, Hebrew, or Russian, natural conception). A (second) group of 150 women who meet inclusion criteria (except smoking) and matched in age, education, gender of infant, and parity to the "smokers" will serve as controls. At recruitment and each time-point, mothers (and their spouses) who agree to participate in the research protocol will be interviewed for smoking habits (Fagerstrom Tolerance Questionnaire, FTQ) as detailed in our previous studies on smoking. At recruitment, women will be explicitly told that we are not encouraging smoking and will provide resources if, at any time, during the study, they want to stop smoking.

Antenatal period (Dr. David Mankuta)

The prenatal session will be carried out at 34-36 weeks of gestation (by last menstrual period and confirmed by early ultrasound) and will consist of 3 phases: (1) waiting room- in which mothers receive instructions, (2) ultrasound- to evaluate limb movement before and after vibroacoustic stimulation (VAS), as well as measures of fetuses' well-being (cardiotocograph test, biophysical profile), and (3) post exam- administration of questionnaires.

Limb movement. Measures of fetal limb movement are good reflections of infant state, are stable from late gestation out to 4-weeks postnatal age 80 , are affected by antenatal stress 81, and forecast infants' state regulation 2 weeks after birth. Ultrasound (ATL 3500 and 5000) will be used to visualize and film the fetus for offline coding of limb movements. To begin testing, infant must be in state 1F, characterized by minimal fetal movement for 2 minutes. When this criterion is met, baseline the VAS (Fetal Acoustic Corometrics Stimulator Model 146; ≈75 HZ, ≈82 db) will be presented for 5 s. Fetal movements will be videotaped with the recorder built into the scanner. During off-line time-event coding, each limb movement will be counted. From these raw counts, we will average the number of movements observed in 10 s intervals during the 1 min prior to (baseline) and during the 5 min after stimulation. Reactivity will be derived by calculating the difference between the mean baseline count and the mean count recorded during the 5 s of stimulation. Regulation will be calculated as (1) the slope of the counts across the post stimulation period (5 minutes), and (2) the difference between the mean baseline count and the mean count of last three 10 second epochs. for first time point. Previous studies have shown limb-counts to be stable (24-36 weeks), reliable, and sensitive to maternal stress.

Questionnaires

Keywords
smoking pregnancy behaviour polymorphisms

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Nov 2007 (estimated)
  2. Study startApr 2008
  3. Study completionDec 2008 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00563966
Sponsor's protocol ID
smokingmothers-HMO-CTIL
Status last verified
Nov 2007
First submitted
25 Nov 2007
Last updated
12 May 2008
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Effects of Smoking on Infant, run by Hadassah Medical Organization at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 May 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact David Mankuta, MD (97226776484, mankutad@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in